PharmiWeb
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
Transgene and NEC will present promising new data from the ongoing randomized Phase I trial of the neoantigen individualized therapeutic cancer vaccine, TG4050 at SITC 2024 on November 9, 2024 ...
7 days ago